Understanding how mutant p53 affects triple negative breast cancer
The Role of the Mutant p53-PARP-MCM Pathway in Triple Negative Breast Cancer
This study is looking at a special version of a protein called p53 in triple negative breast cancer, especially in African American women, to find new ways to detect and treat this aggressive cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hunter College NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10772009 on NIH RePORTER |
What this research studies
This research investigates the role of a specific mutant form of the p53 protein in triple negative breast cancer (TNBC), which is a more aggressive type of breast cancer. The study focuses on how this mutant p53 interacts with other proteins involved in DNA replication and repair, particularly in the context of African American women who are disproportionately affected by TNBC. By exploring these interactions, the research aims to identify new strategies for detecting and treating TNBC. Patients may benefit from insights that could lead to more effective therapies tailored to their specific cancer biology.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with triple negative breast cancer, particularly those of African American descent.
Not a fit: Patients with other types of breast cancer or those without the specific mutant p53 variant may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved detection and treatment options for patients with triple negative breast cancer.
How similar studies have performed: Other research has shown promising results in understanding the role of mutant p53 in cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
New York, United States
- Hunter College — New York, United States (Active)
Researchers
- Principal investigator: Bargonetti, Jill E. — Hunter College
- Study coordinator: Bargonetti, Jill E.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.